Potential targets of energy restriction mimetic agents in cancer cells

References

• 1 Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 134(5), 703–707 (2008).
  Medline CASGoogle Scholar
• 2 Lai IL, Chou CC, Lai PT et al. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis 35(10), 2203–2213 (2014).
  Medline CASGoogle Scholar
• 3 Omar HA, Berman-Booty L, Kulp SK, Chen CS. Energy restriction as an antitumor target. Future Oncol. 6(11), 1675–1679 (2010).
  CASGoogle Scholar
• 4 Omar HA, Berman-Booty L, Weng JR. Energy restriction: stepping stones towards cancer therapy. Future Oncol. 8(12), 1503–1506 (2012).
  CASGoogle Scholar
• 5 Zhu Z, Jiang W, McGinley JN, Thompson HJ. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 65(15), 7023–7030 (2005).
  Medline CASGoogle Scholar
• 6 Ciavardelli D, Rossi C, Barcaroli D et al. Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis. 5, e1336 (2014).
  Medline CASGoogle Scholar
• 7 Omar HA, Salama SA, Arafa el-SA, Weng JR. Antitumor effects of energy restriction-mimetic agents: thiazolidinediones. Biol. Chem. 394(7), 865–870 (2013).
  Medline CASGoogle Scholar
• 8 Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones. J. Biol. Chem. 285(13), 9780–9791 (2010).
  Medline CASGoogle Scholar
• 9 Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11(2), 85–95 (2011).
  Medline CASGoogle Scholar
• 10 Handler P, Bernheim F, Matthews E. Effects of caloric restriction, salt restriction, and role of pituitary and adrenal glands in experimental renal hypertension. Am. J. Phys. 166(3), 528–537 (1951).
  CASGoogle Scholar
• 11 Archer MC. Role of SP transcription factors in the regulation of cancer cell metabolism. Genes Cancer 2(7), 712–719 (2011).
  Medline CASGoogle Scholar
• 12 Ge YQ, Xu XF, Yang B, Chen Z, Cheng RB. Saponins from Rubus parvifolius L. induce apoptosis in human chronic myeloid leukemia cells through AMPK activation and STAT3 inhibition. Asian Pac. J. Cancer Prev. 15, 5455–5461 (2014).
  MedlineGoogle Scholar
• 13 Yu R, Zhang ZQ, Wang B, Jiang HX, Cheng L, Shen LM. Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation. Cancer Cell Int. 14, 49 (2014).
  MedlineGoogle Scholar
• 14 Blagosklonny MV. M(o)TOR of aging: MTOR as a universal molecular hypothalamus. Aging (Albany) 5, 490–494 (2013).
  Medline CASGoogle Scholar
• 15 Al-Wahab Z, Tebbe C, Chhina J et al. Dietary energy balance modulates ovarian cancer progression and metastasis. Oncotarget 5(15), 6063–6075 (2014).
  MedlineGoogle Scholar
• 16 Hsu JL1, Liu SP, Lee CC et al. A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1–AMPK–mTOR signaling pathway. Naunyn Schmiedebergs Arch. Pharmacol. 387(10), 979–990 (2014).
  Medline CASGoogle Scholar
• 17 Li CR, Su JJ, Wang WY et al. Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer. Am. J. Pathol. 182, 363–374 (2013).
  Medline CASGoogle Scholar
• 18 Chen CH, Huang PH, Chu PC et al. Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. J. Biol. Chem. 286, 9968–9976 (2011).
  Medline CASGoogle Scholar
• 19 Lin HY, Kuo YC, Weng YI et al. Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent. Prostate 72(16), 1767–1778 (2012).
  Medline CASGoogle Scholar
• 20 Ghoshal K, Datta J, Majumder S et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 25(11), 4727–4741 (2005).
  Medline CASGoogle Scholar
• 21 Arafa el-SA, Abdelazeem AH, Arab HH, Omar HA. OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro. Acta Pharmacol. Sinica 35(3), 394–400 (2014).
  Medline CASGoogle Scholar
• 22 Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, Lampidis TJ. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother. Pharmacol. 73, 417–427 (2014).
  Medline CASGoogle Scholar
• 23 Sukumar M, Liu J, Ji Y et al. Inhibiting glycolytic metabolism enhances CD8⁺ T cell memory and antitumor function. J. Clin. Invest. 123, 4479–4488 (2013).
  Medline CASGoogle Scholar
• 24 Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nature Rev. Cancer 10(4), 267–277 (2010).
  Medline CASGoogle Scholar
• 25 Berman-Booty LD, Chu PC, Thomas-Ahner JM et al. Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent. Cancer Prev. Res. (Philadelphia) 6(3), 232–241 (2013).
  Medline CASGoogle Scholar
• 26 Frantz S. Drug discovery: playing dirty. Nature 437(7061), 942–943 (2005).
  Medline CASGoogle Scholar
• 27 Omar HA, Arafa El SA, Salama SA, Arab HH, Wu CH, Weng JR. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-kappaB and MAPK signaling pathways. Toxicol. Appl. Pharmacol. 272(3), 616–624 (2013).
  Medline CASGoogle Scholar